Why U.S. Cancer Patients Are Flying to Shanghai for a Lifesaving Drug

When a new cancer drug called Suvotuximab finally cleared China’s regulator in 2023, it sparked a wave of hope for patients who couldn’t wait for the U.S. FDA’s much slower approval process. Max, an American son, flew to Shanghai with his mother Debbie, who has late‑stage brain‑metastatic cancer, to buy the medicine that wasn’t even on the market in the United States. After 19 months on Suvotuximab, Debbie’s tumors stayed largely under control, allowing her to keep working and cherish the time she had left. The story highlights a broader shift: Chinese biotech is no longer just a source of generic drugs and raw ingredients. Thanks to rapid vaccine development during the pandemic, China now runs almost half of the world’s new‑drug trials and offers cutting‑edge therapies like CAR‑T cell treatment to patients from Europe and the U.S. Venture capital is pouring into early‑stage research there, and biotech CEOs are increasingly choosing China or Australia for Phase I trials that would have once been U.S.-centric. For many families, the decision to travel abroad isn’t about a guaranteed cure—Suvotuximab works for roughly half of those who try it—but about buying precious extra months. As word spreads, dozens of Americans are following Max’s example, turning Shanghai into an unexpected lifeline in the fight against cancer.

Read more